Literature DB >> 8463837

Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons.

M Nordlund1, X Gu, M T Shipley, N Ratner.   

Abstract

NF1 patients display CNS abnormalities including learning disabilities, clumsiness, astrocytomas, and abnormalities on magnetic resonance imaging exams. To determine whether the cellular and neuroanatomical distribution of neurofibromin reveals possible function for neurofibromin in the brain, we stained rat brain tissue sections with anti-neurofibromin antibodies. Neurofibromin is highly enriched in large projection neurons, such as cortical and hippocampal pyramidal cells and cerebellar Purkinje cells. Neurofibromin is present in cell bodies and in axons, but is highly enriched in dendrites. Immunoelectron microscopic analysis demonstrates that NF1 is associated with smooth vesiculotubular elements and cisternal stacks and with multivesicular bodies in the cell body and dendrites, but not with the plasma membrane, nucleus, nuclear envelope, Golgi apparatus, mitochondria, or rough endoplasmic reticulum. The preferential localization of neurofibromin to the smooth endoplasmic reticulum, together with evidence that neurofibromin modulates ras GTPase activity, suggests that some, if not all, of the CNS manifestations of NF1 might result from the altered expression of neurofibromin in neurons, perhaps through disruption of Ca2+ signaling, translocation of organelles, or endocytic pathways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8463837      PMCID: PMC6576739     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  19 in total

1.  Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans.

Authors:  Y P Hsueh; A M Roberts; M Volta; M Sheng; R G Roberts
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

2.  Hyperactive interneurons impair learning in a neurofibromatosis model.

Authors:  Kevin J Staley; Anne E Anderson
Journal:  Nat Neurosci       Date:  2009-01       Impact factor: 24.884

3.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

4.  Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.

Authors:  Imanol Arozarena; Fernando Calvo; Piero Crespo
Journal:  Genes Cancer       Date:  2011-03

5.  Growth in North American white children with neurofibromatosis 1 (NF1).

Authors:  J Szudek; P Birch; J M Friedman
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

6.  Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1.

Authors:  Alanna M Kongkriangkai; Christopher King; Lisa J Martin; Emily Wakefield; Carlos E Prada; Geraldine Kelly-Mancuso; Elizabeth K Schorry
Journal:  Am J Med Genet A       Date:  2019-02-08       Impact factor: 2.802

Review 7.  Neurofibromatosis type 1: modeling CNS dysfunction.

Authors:  David H Gutmann; Luis F Parada; Alcino J Silva; Nancy Ratner
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

8.  Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors.

Authors:  Ana Herrero; Mariana Reis-Cardoso; Iñaki Jiménez-Gómez; Carolanne Doherty; Lorena Agudo-Ibañez; Adán Pinto; Fernando Calvo; Walter Kolch; Piero Crespo; David Matallanas
Journal:  Small GTPases       Date:  2018-01-15

Review 9.  Molecular genetics of neurofibromatosis type 1 (NF1).

Authors:  M H Shen; P S Harper; M Upadhyaya
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

10.  Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor.

Authors:  T A Rizvi; S Akunuru; G de Courten-Myers; R C Switzer; M L Nordlund; N Ratner
Journal:  Brain Res       Date:  1999-01-16       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.